The purpose of this study is to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures, and change in biomarkers. There are six visits required for this study. These visits will happen at the same time as regularly scheduled visits to the BNI ALS Multidisciplinary Clinic, and will occur approximately every 3 months. Overall, participants may be in the research study for about 15 months.
Principal Investigators: Jeremy Shefner, MD, PhD